BMC Bioinformatics

Proceedings

Very Important Pool (VIP) genes – an application for microarray-based molecular signatures

Zhenqiang Su[1], Huixiao Hong[1], Hong Fang[2], Leming Shi[1], Roger Perkins[2] and Weida Tong*[1]

Address: [1]Center for Toxicoinformatics, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration (FDA), 3900 NCTR Road, Jefferson, AR 72079, USA and [2]Z-Tech, an ICF International Company at FDA's National Center for Toxicological Research, Jefferson, AR 72079, USA

Email: Zhenqiang Su - zhenqiang.su@fda.hhs.gov; Huixiao Hong - huixiao.hong@fda.hhs.gov; Hong Fang - hong.fang@fda.hhs.gov; Leming Shi - leming.shi@fda.hhs.gov; Roger Perkins - roger.perkins@fda.hhs.gov; Weida Tong* - weida.tong@fda.hhs.gov

* Corresponding author

This article is available from: http://www.biomedcentral.com/1471-2105/9/S9/S9

Abstract

Background: Advances in DNA microarray technology portend that molecular signatures from which microarray will eventually be used in clinical environments and personalized medicine. Derivation of biomarkers is a large step beyond hypothesis generation and imposes considerably more stringency for accuracy in identifying informative gene subsets to differentiate phenotypes. The inherent nature of microarray data, with fewer samples and replicates compared to the large number of genes, requires identifying informative genes prior to classifier construction. However, improving the ability to identify differentiating genes remains a challenge in bioinformatics.

Results: A new hybrid gene selection approach was investigated and tested with nine publicly available microarray datasets. The new method identifies a Very Important Pool (VIP) of genes from the broad patterns of gene expression data. The method uses a bagging sampling principle, where the re-sampled arrays are used to identify the most informative genes. Frequency of selection is used in a repetitive process to identify the VIP genes. The putative informative genes are selected using two methods, t-statistic and discriminatory analysis. In the t-statistic, the informative genes are identified based on p-values. In the discriminatory analysis, disjoint Principal Component Analyses (PCAs) are conducted for each class of samples, and genes with high discrimination power (DP) are identified. The VIP gene selection approach was compared with the p-value ranking approach. The genes identified by the VIP method but not by the p-value ranking approach are also related to the disease investigated. More importantly, these genes are part of the pathways derived from the common genes shared by both the VIP and p-ranking methods. Moreover, the binary classifiers built from these genes are statistically equivalent to those built from the top 50 p-value ranked genes in distinguishing different types of samples.

Conclusion: The VIP gene selection approach could identify additional subsets of informative genes that would not always be selected by the p-value ranking method. These genes are likely to be additional true positives since they are a part of pathways identified by the p-value ranking method and expected to be related to the relevant biology. Therefore, these additional genes derived from the VIP method potentially provide valuable biological insights.

Background

DNA microarray technology [1,2] has rapidly advanced due to the intrinsic and unprecedented ability to simultaneously measure gene expression on a whole genome basis. Microarray technology continues to develop and is widely cited as offering much utility for translational science, from improved drug discovery, including target discovery, to improved clinical diagnostics and disease stage determination, prognostics and treatment selection, and more. With the prospect of microarray-derived biomarkers being applied in clinical applications, the bar is substantially raised for identification of informative genes enabling accurate classifiers, and efforts to this end are prevalent in the literature [3-11]. More specifically, there is a compelling need to identify a subset of genes from among the more than 20,000 in the entire genome that allow robust classifiers to be developed. The difficulty and challenge is to overcome the intrinsic characteristics of microarray data that contains a substantially small number of samples when compared to the number of genes [12,13]. These characteristics lead to the risk of fitting to noise as genes with high variability unrelated to phenotype masquerade as informative genes. The truly differentiating signals derived from small numbers of experimental replicates are difficult to distinguish in the sea of noise, leading to the appearance of unstable (i.e., non-reproducible) significant gene lists [14-16].

Gene selection is synonymous with feature selection or variable selection in machine learning, a process extensively used to mitigate the so called "curse of dimensionality" [17-20]. Generally, gene selection is done for either hypothesis testing or hypothesis generation. Selecting a subset of genes as molecular signatures or biomarkers that could be used for developing a generalized and accurate classifier for differentiating phenotypes is a hypothesis testing process [21], wherein rigorous validation is needed. On the other hand, identifying a list of putatively relevant genes related to a phenotype or endpoint of interest for subsequent research is a hypothesis generating process [22], wherein validation of the genes is much more relaxed; the genes so identified often shed light on the fundamental molecular mechanisms and biological processes under study.

Selecting and validating an "optimal" set of genes for a molecular signature or biomarker for a robust classifier is a complicated and time-consuming task. An exhaustive search encompassing all possible gene subsets to find the set yielding the smallest error can be an intractable computational task. Worse still, because the number of genes far outnumber samples, the potential for fitting to random noise is high, making stringent testing and validation essential [23,24].

Most methods to select informative genes for classification model development reported in the literature rely on ranked genes by fold change, correlation coefficient, or p-value from a t-statistic, Wilcoxon statistic, or analysis of variance (ANOVA), or some combination of these [22,25-30]. To a greater or lesser degree, all of these methods yield an informative gene list varying on the sample size, which has led doubt on microarray reliability [14-16]. In theory, true phenotype differentiating genes should be expected to express consistently with each other regardless of the sample size. In other words, the list of informative genes as well as the underlying mechanisms inferred by these genes should have nothing to do with the sample size.

In this study, a bagging [31] based new hybrid gene selection approach was investigated to identify informative genes. The rationale of the approach is that informative genes should consistently show significance for different variations of sample size. Accordingly, many re-sampling iterations are conducted to generate different variations of sample size and the frequency of genes exhibiting significance throughout the iterations formed the basis for identification of the informative genes that are considered as a Very Important Pool (VIP) of genes. In reality, the VIP genes can be identified using any existing gene selection approach or their combinations and can be used to derive molecular signatures to build robust classifiers with good generalization capability, or to narrow subsequent research to reveal relevant, fundamental molecular mechanisms in biological processes. In this study, t-statistic and discriminatory analysis are used to evaluate the significance of genes. In the t-statistic, the significant genes are identified based on p-values. In the discriminatory analysis, disjoint Principal Component Analyses (PCAs) are conducted for each class of samples, and those genes with high discrimination power (DP) [32] are identified as significant genes. The VIP genes are those having high frequency of showing significance in the re-sampling iterations. The utility of the proposed approach was demonstrated with nine diverse microarray datasets for identifying the informative genes for classifier development and compared with commonly used p-value ranking gene selection approaches.

Results

The VIP gene selection approach for microarray based molecular signatures was applied to the nine publicly available microarray gene expression datasets described in Table 1. For the purpose of comparison, the p-value ranking method was also used. For each dataset, an unbiased sample splitting, gene selection, and validation dataset prediction process as depicted in Figure 1 was carried out. Briefly, a dataset is first randomly split into a training set with two thirds of the samples and a validation set with

Figure 1
The flowchart for the classifier development and validation using three gene sets: (A) Top 50 p-value ranked genes; (B) Top 50 VIP genes; and (C) the unique VIP genes. Specifically, the data set is first randomly divided into two thirds of samples for training and the remainder for validation. Next, three sets of genes are generated solely based on the training set, and are subsequently used to develop Nearest-Centroid classifiers. Lastly, the classifiers are used to predict the validation samples and their respective prediction performance measured by accuracy (Acc), specificity (Spec), sensitivity (Sens), and Matthew's correlation coefficient (MCC) are calculated. The process is repeated 50 times and the averaged performance metrics are reported in Table 2.

the remaining samples. With validation samples set aside, gene selection and classifier development are done using the training samples. Two lists of 50 genes are selected, one using the proposed VIP gene selection approach and the other using p-value ranking. The p-value ranking is

based on an unpaired, two-tailed t-statistic with pooled variance estimate. In order to exam whether the VIP gene selection approach can identify informative genes or not, three sets of classifiers were generated, one for the VIP genes, one for the p-value genes and another for the genes uniquely identified by the VIP method (called unique genes hereafter). A Nearest-Centroid[33] classification method was used to develop classifiers. These classifiers are applied to predict the validation samples. The prediction performance of classifiers were compared by accuracies, specificities, sensitivities, and the Matthew's correlation coefficients (MCCs). The definitions of these measures are given in the section titled "materials and methods". The sample splitting, gene selection, and validation dataset prediction steps were repeated 50 times for adequate statistics.

We first compared the classifiers based on the VIP genes with those from the p-value ranking. As shown in Table 2, the VIP classifiers exhibited somewhat better performance compared to the classifiers from the p-value selected genes. The p-values from t-statistic for accuracy, specificity, sensitivity and MCC between two groups of classifiers (the VIP classifiers versus the p-value ranking classifiers) are 0.0027, 0.32, 0.059, and 0.0092, respectively. Therefore, at the 0.05 confidence level, the improvement of classifier measured in MCC and accuracy is significant, but not for specificity and sensitivity. The results indicate that the VIP genes may convey more, but not less, biologically relevant information than the p-value selected genes.

Next, to determine whether the unique genes indeed contribute to the sample differentiation and thus biological relevance, we compared prediction performance of the classifiers built from unique genes with those built from the p-value ranked genes across the nine datasets. The average number of unique genes for each dataset is also listed in Table 2. It was shown that the average perform-

Table 1: Nine microarray datasets used in the study.

Name	Cancer type	Prediction task	Sample size	Number of events	Number of genes	Reference
Beer	Lung adenocarcinoma	Survival	86	24	6532	[48]
Bhattacharjee	Lung adenocarcinoma	4-year survival	62	31	5403	[49]
Chen	Hepatocellular carcinoma	Tumors	156	82	3964	[50]
Pomeroy	Medulloblastoma	Medulloblastoma survival	60	21	7129	[52]
Rosenwald	Non-Hodgkin lymphoma	Survival	240	138	7399	[53]
Shipp	Diffuse large b-cell lymphoma (DLBCL)	Cured	58	32	6817	[54]
Singh	Prostate cancer	Tumors	102	52	12600	[55]
Yeoh	Acute lymphocytic leukaemia	Relapse-free survival	233	32	12236	[56]
van't Veer	Breast cancer	5-year metastasis-free survival	97	46	4948	[57]

Table 2: Comparison of prediction performance for Nearest-Centroid classifiers built from unique VIP genes, top 50 p-value ranked genes, and 50 VIP genes. The classifier performance metrics, including accuracy (Acc), specificity (Spec), Sensitivity (Sens), and Matthew's correlation coefficient (MCC) were calculated based on averages of 50 repetitions of sample splitting, gene selection, and validation dataset prediction.

Data set	Number of genes	Unique VIP genes				50 p-value ranked genes				50 VIP genes			
		Acc (%)	Spec (%)	Sens (%)	MCC	Acc (%)	Spec (%)	Sens (%)	MCC	Acc (%)	Spec (%)	Sens (%)	MCC
Beer	15	64.7	38.3	74.0	0.13	64.7	38.3	74.0	0.12	65.2	35.4	75.6	0.11
Bhattacharjee	17	58.7	57.8	59.6	0.18	58.0	59.2	56.8	0.16	58.6	59.4	57.8	0.18
Chen	14	96.5	99.9	93.6	0.93	95.3	100.0	91.2	0.91	95.8	100.0	92.1	0.92
Pomeroy	20	60.8	54.0	64.2	0.19	60.8	51.7	65.3	0.18	62.4	55.7	65.8	0.22
Rosenwald	18	55.5	58.1	53.6	0.12	56.8	63.2	52.2	0.15	57.4	62.3	53.8	0.16
Shipp	18	51.6	50.8	52.5	0.03	47.9	51.8	43.0	-0.05	49.0	47.4	51.0	-0.02
Singh	15	94.3	98.3	91.7	0.89	98.1	100.0	96.9	0.96	97.8	100.0	96.4	0.96
Yeoh	22	74.6	37.8	80.2	0.15	78.2	31.0	85.4	0.15	80.2	35.0	87.0	0.21
van't Veer	20	64.8	64.8	64.9	0.30	65.2	61.5	68.6	0.31	66.9	66.1	67.6	0.34

ance metrics (accuracy, specificity, sensitivity, and MCC) for classifiers built from unique genes (number from 14 to 22) are not very different from those built from top 50 p-value ranked genes for all nine datasets. The difference of each pair of average performance metrics is respectively tested across nine datasets with a null hypothesis that the compared performance metrics (accuracy, specificity, sensitivity, or MCC) is not very different from each other by using a paired and two-tailed t-statistic. The p-values given by t-statistic are 0.63, 0.77, 0.95, and 0.81 for accuracy, specificity, sensitivity, and MCC respectively. Apparently, the differences of all prediction performance metrics among classifiers are not significant at the 0.05 confidence level. This suggests that the unique VIP genes are statistically equivalent as those identified by p-value ranking in distinguishing different types of samples. Therefore, these unique genes could be an additional subset of genes which are equally as important as those selected with p-value ranking. The existence of additional subsets of classifying genes may imply that there exist multiple biological processes for studied endpoints or co-factors.

Lastly, to gain more understanding of the VIP genes in terms of biology related to the investigated dataset, we further examined the unique genes as well as the common genes shared by the p-value method in the van't Veer dataset using PathArt http://www.jubilantbiosys.com/ppa.htm through the FDA genomic tool, ArrayTrack http://www.fda.gov/nctr/science/centers/toxicoinformatics/ArrayTrack/. PathArt is a pathway analysis tool that contains disease related canonical pathways manually created from the literature. The van't Veer dataset contains 24 unique genes and 26 common genes. Of 24 unique genes, ten genes were found in PathArt and were listed in Table 3. Most of these ten genes involve biological processes related to various cancers; for example, IGFBP5 and MMP9 are directly related to breast cancer. We also examined the pathways associated with the 26 common genes and found seven unique genes were involved in seven pathways identified by the common genes (Table 4). These results demonstrate that the unique genes not identified by the p-value ranking could convey additional important information for biological interpretation.

Discussion

Quantitatively assessing the effectiveness of gene selection methods can be problematic owing to several limitations among which selection bias caused by information leakage from training phase to validation phase figures prominently [24]. The most severe bias was described by Ambroise *et al.* [21] and Simon *et al.* [34] as occurring when identifying genes from the entire dataset (i.e., training set and validation set) and using them in cross-validation. Wessels *et al.* [35] and Lai *et al.* [24] describe a less severe bias. Typically, the training samples are used to generate a series of gene subsets, while the performance of a classifier trained with the training samples and tested with the validation samples is applied to estimate the informativeness of each gene subset. The bias derives from the fact that the validation samples are used to select the best performing gene subset. Since optimization of the gene subset is part of the training process, selection of the best gene subset should be conducted with the training samples only. This process as shown in Figure 1 has been carried out in this study to assess the utility of the proposed VIP gene selection method by entirely avoiding bias due to information leakage from validation dataset in training phase.

Classification method selection is another important aspect of developing predictive models from microarray expression data. Many classifiers are created with one or more adjustable parameters that affect not only the prediction accuracy but also the complexity of the classifiers

and the computational expense of their use. The proper adjustment of the tuneable parameters can affect the fairness of comparative predictive performance assessments. For example, the relatively simple k-Nearest Neighbour (KNN)[36] classification method has a tuneable k in the prediction rules. Adjusting k requires some validation process be carried out. Generally, different validation strategies such as leave-one-out cross validation, k-Fold cross-validation, or Monte Carlo validation, will yield different preferred values of k. Other classification approaches, such as Support Vector Machine (SVM) [37], Partial Least Squares Discriminant Analysis (PLS-DA) [38], Random Forest (RF)[22], and Artificial Neural Networks (ANN) [39] are considerably more complex by comparison, causing more work and computational cost. According to Wessels *et al.* [35], Michiels *et al.* [33], and Lai *et al.* [24], choosing a classification method with a limited complexity can help prevent over-training, thus providing a more robust predictor. In this study, the simple classification approach Nearest-Centroid was used to develop and compare classifiers based on unique VIP genes and top 50 p-value ranked genes. Since the method lacks a tuneable parameter, risks of overtraining are lessened compared to other methods, as are the chances that differences in prediction accuracy are due to method rather than selected genes.

Commonly used gene selection approaches in DNA microarray data analysis, such as p-value ranking or fold change ranking and others, assume that all genes are stochastic variables that are unrelated to each for purposes of calculating significance. This assumption is inconsistent with the actual biological processes where most genes have some interdependency to and are interlinked with other genes through complex mechanisms and pathways. In contrast, the proposed VIP gene selection approach uses both DPs and p-values to assess the discriminatory capability of genes in differentiating sample types. DPs are calculated from two independent PCAs that fuse discriminating information across whole genes. The interdependence and interlinking effects among genes are embedded within the DP calculation, enhancing rather than reducing many aspects of actual biological processes. Furthermore, the bagging re-sampling technique, which has been used to analyze microarray data for clustering [40-42] and classification [43-46], is used here to mitigate the chance selection of genes. Compared with p-value ranking-type gene selection approaches, the proposed VIP gene selection has great potential to select additional informative genes that can be useful for either biological insights or to improve the prediction performance of classifiers.

Conclusion
The new hybrid gene selection approach was investigated for identifying VIP genes from nine diverse gene expres-

sion datasets. The VIP gene selection approach quantifies discriminatory capability for differentiating sample classes using both discrimination analysis and p-value ranking through a bagging sampling process. The classifiers built from those unique VIP genes showed comparable prediction capability to those built from the top 50 t-statistic based p-value ranked genes in predicting the types of unknown samples. Therefore, the VIP gene selection approach could provide an additional subset of genes which are of equivalent performance as those selected with the t-statistic based p-value ranking. The subset of VIP genes could convey additional biological information in terms of associated biological pathways and mechanisms during hypothesis generation. Similarly, the VIP genes could be used to improve molecular fingerprints for use in clinical biomarkers.

Materials and methods
Microarray datasets and software
Nine publicly available microarray datasets were used to demonstrate the relative prediction performance of the proposed VIP gene selection approach. The datasets are from Alon *et al.* [47], Beer *et al.* [48], Bhattacharjee *et al.* [49], Chen *et al.* [50], Gordon *et al.* [51], Pomeroy *et al.* [52], Resenwald *et al.* [53], Shipp *et al.* [54], Singh *et al.* [55], Yeoh *et al.* [56], and van't Veer *et al.* [57], that for convenience are hereafter respectively referred to as "Alon", "Beer", "Bhattacharjee", "Chen", "Gordon", "Pomeroy", "Resenwald", "Shipp", "Singh", "Yeoh", and "van't Veer"; information for each dataset is given in Table 1.

The VIP gene selection approach was developed using the programming language Matlab® 7.0, running on a DELL™ Precision 490 workstation equipped with two Intel® Dual Core Xeon™ 3.0 GHz processors and 2 GB of memory. The Matlab codes are available upon request.

The biological interpretation of genes was conducted using PathArt http://www.jubilantbiosys.com/ppa.htm through the FDA genomic tool, ArrayTrack http://www.fda.gov/nctr/science/centers/toxicoinformatics/ArrayTrack/.

Algorithm
The VIP gene selection approach combines discriminatory powers derived from two independent principal component analyses and p values from t-statistic to filter genes based on a bagging, re-sampling technique. The algorithmic process is depicted in Figure 2, where the training dataset is composed of n_1 samples of class 1 and n_2 samples of class 2. Samples of class 1 and class 2 are represented by the matrices X_1 and X_2, respectively. The VIP genes are chosen through the following steps:

Table 3: Pathways identified for the unique VIP genes and common genes for the van't Veer dataset.

	Accession number (Symbol)	Full Name	Pathway name	Category (e.g. disease)
Unique VIP genes	AF055033 (IGFBP5)	Insulin-like growth factor binding protein 5	Estrogen signaling pathway	Breast cancer
			IGF signaling pathway	Lung cancer
	NM_000599 (IGFBP5)		AR mediated pathway; insulin-like growth factor-1 signaling pathway	Prostate cancer
			Responsive genes	Ovarian cancer
	NM_000017 (ACADS)	Acyl-coenzyme A dehydrogenase, C-2 to C-3 short chain	Responsive genes	Colon cancer
	NM_004994 (MMP9)	Matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase)	Heregulin, and CXCL12 signaling pathway	Breast cancer
			Bombesin, IL10, IL8, TGFbeta, and HGF signaling pathway; responsive genes	Prostate cancer
			Responsive genes; thrombospondin signaling pathway	Pancreatic cancer
			Gastrin, HGF, and IL4 signaling pathway; integrin, and UPAR mediated pathway	Colon cancer
			Responsive genes	Chronic myeloid leukemia
			EGF signaling pathway; VEGF mediated pathway; responsive genes	Ovarian cancer
			HGF, and IL6 signaling pathway; Responsive genes	Lung cancer
	NM_001197 (BIK)	BCL2-interacting killer (apoptosis-inducing)	p53 mediated pathway	Colon cancer
	NM_001809 (CENPA)	Centromere protein A	Responsive genes	Lung cancer
			p21 mediated pathway	Cell-cycle
	NM_002808 (PSMD2)	Proteasome (prosome, macropain) 26S subunit, non-ATPase, 2	Tat signaling pathway	Acquired immuno deficiency syndrome
	NM_004336 (BUB1)	BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast)	Spindle Checkpoint Pathway	Cell-cycle
	NM_004626 (WNT11)	Wingless-type MMTV integration site family, member 11	Cell-cell signaling pathway	Others
			WNT receptor signaling pathway	Others
	NM_004887 (CXCL14)	Chemokine (C-X-C motif) ligand 14	Signal transduction pathway	Others
Common genes	AL050227 (PTGER3)	Prostaglandin E receptor 3 (subtype EP3)	Estrogen signaling pathway	Breast cancer
			PGE2 mediated pathway	Lung cancer
	NM_006763 (BTG2)	BTG family, member 2	Estrogen signaling pathway	Breast cancer
			Responsive genes	Prostate cancer
			CEBP alpha mediated pathway	Chronic myeloid leukemia
			Miscellaneous	DNA repair
			BTG mediated pathway	Cell-cycle
	NM_003862 (FGF18)	Fibroblast growth factor 18	WNT signaling pathway	Colon cancer
	NM_006115 (PRAME)	Preferentially expressed antigen in melanoma	Responsive genes	Ovarian cancer
	X05610 (COL4A2)	Collagen, type IV, alpha 2	Responsive genes	Glioblastoma
	NM_003981 (PRC1)	Protein regulator of cytokinesis 1	p21 mediated pathway	Cell-cycle
	NM_006027 (EXO1)	Exonuclease 1	p21 mediated pathway	Cell-cycle
	NM_002811 (PSMD7)	Proteasome (prosome, macropain) 26S subunit, non-ATPase, 7	Tat signaling pathway	Acquired immuno deficiency syndrome

Table 4: The pathways involved with both unique VIP genes and common genes for the van't Veer dataset

Pathway name	Unique gene	Common gene	Category
Estrogen signaling pathway	IGFBP5 (AF055033, NM_000599)	BTG2, PTGER3	Breast cancer
p21 mediated pathway	BUB1B, CENPA	EX01, PRC1	Cell-cycle
CEBPalpha mediated pathway	MMP9	BTG2	Chronic myeloid leukemia
WNT signaling pathway	WNT11	FGF18	Colon Cancer
Tat signaling pathway	PSMD2	PSMD7	Acquired immuno deficiency syndrome
Responsive genes	MMP9	BTG2	Prostate cancer
Responsive genes	MMP9, IGFBP5 (AF055033, NM_000599)	PRAME	Ovarian cancer

1. Randomly select 75% of samples from the training data, $\mathbf{X}_1$ and $\mathbf{X}_2$, using a bagging, re-sampling strategy. The selected samples are represented with $\mathbf{X}_{1m}$ for class 1 and $\mathbf{X}_{2m}$ for class 2.

2. Rank genes by their p-values and only keep the top 100 genes for next step. P-values are calculated from a two-tailed and unpaired t-statistic with pooled variance estimate (i.e., equal variances or homoscedastic assumption) on $\mathbf{X}_{1m}$ and $\mathbf{X}_{2m}$. The remaining data are represented by X'_{1m} and X'_{2m}, respectively.

3. Rank genes based on their discrimination powers (DPs) and the increment the frequencies of the top 50 genes by one. The calculation of DPs is described in detail in the next section "calculation of discrimination power".

4. Repeat steps one through three 100 times.

5. Rank genes by frequencies and choose the top 50 genes as VIP genes.

Calculation of discrimination power
DPs are calculated from two independent principal component analyses (PCAs). PCA is performed on each p-value-filtered data, X'_{1m} and X'_{2m} from step 2. The optimum number of components for each PCA is determined using Malinowski's factor indicator function (IND) [58] with eqs. (1) – (3):

$$\mathbf{X} = \mathbf{TP} \tag{1}$$

$$RE_k = \sqrt{\frac{\sum_{i=k+1}^{g} \lambda_i}{p(n-k)}} \tag{2}$$

$$IND_k = \frac{RE_k}{(n-k)^2}, \tag{3}$$

where $\mathbf{X}$ is either X'_{1m} and X'_{2m}; $\mathbf{T}$ and $\mathbf{P}$ are the score and loading matrices of the PCA; λ_i is the ith eigenvalue of the total g eigenvalues; and n and p are the number of samples and the number of genes in the matrix $\mathbf{X}$, respectively. The optimum number (k) of components for the PCA is the one that yields the minimum *IND* value. The discrimination power (DP_j) for a gene j can be calculated with eq. (4):

$$DP_j = \frac{(\mathbf{e}_j^{12})^{\mathrm{T}}(\mathbf{e}_j^{12}) + (\mathbf{e}_j^{21})^{\mathrm{T}}(\mathbf{e}_j^{21})}{(\mathbf{e}_j^{11})^{\mathrm{T}}(\mathbf{e}_j^{11}) + (\mathbf{e}_j^{22})^{\mathrm{T}}(\mathbf{e}_j^{22})}, \tag{4}$$

where $\mathbf{e}_j^{11}$, $\mathbf{e}_j^{12}$, $\mathbf{e}_j^{22}$, and $\mathbf{e}_j^{21}$ are the j columns of matrices $\mathbf{E}_{11}$, $\mathbf{E}_{12}$, $\mathbf{E}_{22}$, and $\mathbf{E}_{21}$, respectively. $\mathbf{E}_{11}$ and $\mathbf{E}_{12}$ are the residue matrices after projecting X'_{1m} into the PCA spaces of class 1 and class 2, respectively, while $\mathbf{E}_{22}$ and $\mathbf{E}_{21}$ are the residue matrices after projecting X'_{2m} into the PCA spaces of class 1 and class 2, respectively. A residue matrix is calculated with eq. (5).

$$\mathbf{E} = \mathbf{X} - \mathbf{XPP}^{\mathrm{T}}, \tag{5}$$

where $\mathbf{E}$ is one of the four residue matrices $\mathbf{E}_{11}$, $\mathbf{E}_{12}$, $\mathbf{E}_{22}$, and $\mathbf{E}_{21}$.

Prediction performance
The prediction performance of a Nearest-Centroid classifier in this study is characterized with four metrics: accuracy, specificity, sensitivity, and the Matthew's correlation coefficient (MCC). The metrics can be calculated from the prediction confusion matrix shown in Table 5 as follows:

$$Accuracy = \frac{TP+TN}{TP+TN+FP+FN} \tag{6}$$

$$Specificity = \frac{TN}{TN+FP} \tag{7}$$

```
                          ( Start )
                              │
                              ▼
              ┌───────────────────────────────────┐
              │  Training data: X₁, X₂, m = 1      │
              └───────────────────────────────────┘
                              │
                              ▼
       ┌──────────────────────────────────────────────────┐
    ┌─▶│  Select 75% of samples (X₁ₘ, X₂ₘ) from X₁ and X₂  │
    │  │  independently using bagging re-sampling strategy  │
    │  └──────────────────────────────────────────────────┘
    │                         │
    │                         ▼
    │     ┌────────────────────────────────────────┐
    │     │  Rank genes by their p-values and keep   │
    │     │  the top 100 genes (X'₁ₘ and X'₂ₘ) for  │
    │     │  next step.                              │
    │     └────────────────────────────────────────┘
    │                         │
    │                         ▼
    │     ┌────────────────────────────────────────┐
    │     │  Perform principal component analyses    │
    │     │  (PCAs) on p-value filtered data, X'₁ₘ  │
    │     │  and X'₂ₘ, respectively                 │
    │     └────────────────────────────────────────┘
    │                         │
    │                         ▼
    │  ┌───────────────────────────────────────────────┐
    │  │  Determine the optimum number of components    │
    │  │  for each PCA according to Malinowski's factor │
    │  │  indicator function                            │
    │  └───────────────────────────────────────────────┘
    │                         │
    │                         ▼
    │     ┌────────────────────────────────────────┐
    │     │  Calculate the residue matrices E₁₁,    │
    │     │  E₁₂, E₂₂, E₂₁ based on two PCAs         │
    │     └────────────────────────────────────────┘
    │                         │
    │                         ▼
    │     ┌────────────────────────────────────────┐
    │     │  Calculate discrimination powers (DPs)   │
    │     │  for each gene based on the four residue │
    │     │  matrices                                │
    │     └────────────────────────────────────────┘
    │                         │
    │                         ▼
    │     ┌────────────────────────────────────────┐
    │     │  Rank genes based on their DPs, the      │
    │     │  frequencies of the top 50 genes         │
    │     │  increase by one                         │
    │     └────────────────────────────────────────┘
    │                         │
    │  No                     ▼
    └─────────────◇ m= m +1; m > 100? ◇
                             │
                             │ Yes
                             ▼
              ┌────────────────────────────────────┐
              │  Rank genes on their frequencies.   │
              │  The top 50 genes are identified.   │
              └────────────────────────────────────┘
                             │
                             ▼
                          ( End )
```

Figure 2

The detailed process for identifying a very important pool (VIP) of genes. X_1 and X_2 are, respectively, the gene expression profiles for class 1 samples and class 2 samples in the training set. X_{1m} and X_{2m} are samples randomly selected from X_1 and X_2 in the mth bagging step. X'_{1m} and X'_{2m} are the genes remaining after filtering genes from X_{1m} and X_{2m}, respectively. Malinowski's factor indicator function (IND) is calculated with equations $RE_k = \sqrt{\sum_{i=k+1}^{g} \lambda_i / p(n-k)}$ and $IND_k = RE_k/(n-k)^2$, where λ_i is the ith eigenvalue of the total g eigenvalues; n is the number of samples and p is the number of genes. The optimum number (k) of components corresponds to the IND minimum. E_{11} and E_{21} are the residue matrices after projecting X_{1m} and X_{2m} into the PCA space for class 1, respectively, while E_{22} and E_{12} are the residue matrices after projecting X_{2m} and X_{1m} into the PCA space for class 2, respectively. The discrimination power (DP) of a gene j is calculated with the equation:
$DP_j = [(e_j^{12})^{\mathrm{T}}(e_j^{12}) + (e_j^{21})^{\mathrm{T}}(e_j^{21})] / [(e_j^{11})^{\mathrm{T}}(e_j^{11}) + (e_j^{22})^{\mathrm{T}}(e_j^{22})]$, where e_j^{11}, e_j^{12}, e_j^{22}, and e_j^{21} are the j columns of residue matrices E_{11}, E_{12}, E_{22}, and E_{21}, respectively.

Table 5: The prediction confusion matrix

Observation	Prediction	
	+I	-I
+I	TP (True positive)	FN (False negative)
-I	FP (False positive)	TN (True negative)

$$Sensitivity = \frac{TP}{TP+FN} \qquad (8)$$

$$MCC = \frac{TP \times TN - FP \times FN}{\sqrt{(TP+FP) \times (TP+FN) \times (TN+FP) \times (TN+FN)}}, \qquad (9)$$

where TP, TN, FP, FN are respectively the numbers of true positive, true negative, false positive, and false negative predictions in the confusion matrix (Table 5).

Disclaimer
The views presented in this article do not necessarily reflect those of the US Food and Drug Administration.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
ZS had the original idea, developed the method, did all calculations and data analysis, and wrote the first draft of manuscript. WT had the original idea, discussed on data analysis and presentation of results. HF, HH, LS, and RP involved in discussion on data analysis, verified some of the calculations and assisted with writing the manuscript. All authors read and approved the final manuscript.

Acknowledgements

References
1. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, *et al.*: **Expression monitoring by hybridization to high-density oligonucleotide arrays.** *Nat Biotechnol* 1996, **14(13):**1675-1680.
2. Schena M, Shalon D, Davis RW, Brown PO: **Quantitative monitoring of gene expression patterns with a complementary DNA microarray.** *Science* 1995, **270(5235):**467-470.
3. Quackenbush J: **Computational approaches to analysis of DNA microarray data.** *Methods Inf Med* 2006, **45(Suppl 1):**91-103.
4. Quackenbush J: **Computational analysis of microarray data.** *Nat Rev Genet* 2001, **2(6):**418-427.
5. Dopazoa J, Zandersb E, Dragonib I, Amphlettb G, Falci F: **Methods and approaches in the analysis of gene expression data.** *Journal of Immunological Methods* 2001, **250(1–2):**93-112.
6. Butte A: **The use and analysis of microarray data.** *Nat Rev Drug Discov* 2002, **1(12):**951-960.
7. Hackl H, Sanchez Cabo F, Sturn A, Wolkenhauer O, Trajanoski Z: **Analysis of DNA microarray data.** *Curr Top Med Chem* 2004, **4(13):**1357-1370.
8. Lee KE, Sha N, Dougherty ER, Vannucci M, Mallick BK: **Gene selection: a Bayesian variable selection approach.** *Bioinformatics* 2003, **19(1):**90-97.
9. Ding C, Peng H: **Minimum redundancy feature selection from microarray gene expression data.** *J Bioinform Comput Biol* 2005, **3(2):**185-205.
10. Gould J, Getz G, Monti S, Reich M, Mesirov JP: **Comparative gene marker selection suite.** *Bioinformatics* 2006, **22(15):**1924-1925.
11. Chen JJ, Tsai CA, Tzeng S, Chen CH: **Gene selection with multiple ordering criteria.** *BMC Bioinformatics* 2007, **8:**74.
12. Mukherjee S, Roberts SJ: **A theoretical analysis of the selection of differentially expressed genes.** *J Bioinform Comput Biol* 2005, **3(3):**627-643.
13. Su Z, Hong H, Perkins R, Shao X, Cai W, Tong W: **Consensus analysis of multiple classifiers using non-repetitive variables: diagnostic application to microarray gene expression data.** *Comput Biol Chem* 2007, **31(1):**48-56.
14. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, *et al.*: **The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements.** *Nat Biotechnol* 2006, **24(9):**1151-1161.
15. Shi L, Tong W, Fang H, Scherf U, Han J, Puri RK, Frueh FW, Goodsaid FM, Guo L, Su Z, *et al.*: **Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential.** *BMC Bioinformatics* 2005, **6(Suppl 2):**S12.
16. Shi L, Perkins RG, Fang H, Tong W: **Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential.** *Curr Opin Biotechnol* 2008, **19(1):**10-18.
17. Jain AK, Duin RPW, Mao J: **Statistical Pattern Recognition: A Review.** *IEEE Transactions on Pattern Analysis and Machine Intelligence* 2000, **22(1):**4-37.
18. Raudys SJ, Jain AK: **Small Sample Size Effects in Statistical Pattern Recognition: Recommendations for Practitioners.** *IEEE Transactions on Pattern Analysis and Machine Intelligence* 1991, **13(3):**252-264.
19. Zhang HH, Ahn J, Lin X, Park C: **Gene selection using support vector machines with non-convex penalty.** *Bioinformatics* 2006, **22(1):**88-95.
20. Bluma AL, Langley P: **Selection of relevant features and examples in machine learning.** *Artificial Intelligence* 1997, **97(1–2):**245-271.
21. Ambroise C, McLachlan GJ: **Selection bias in gene extraction on the basis of microarray gene-expression data.** *Proc Natl Acad Sci USA* 2002, **99(10):**6562-6566.
22. Diaz-Uriarte R, Alvarez de Andres S: **Gene selection and classification of microarray data using random forest.** *BMC Bioinformatics* 2006, **7:**3.
23. Ein-Dor L, Kela I, Getz G, Givol D, Domany E: **Outcome signature genes in breast cancer: is there a unique set?** *Bioinformatics* 2005, **21(2):**171-178.
24. Lai C, Reinders MJ, van't Veer LJ, Wessels LF: **A comparison of univariate and multivariate gene selection techniques for classification of cancer datasets.** *BMC Bioinformatics* 2006, **7:**235.
25. Li L, Weinberg CR, Darden TA, Pedersen LG: **Gene selection for sample classification based on gene expression data: study of sensitivity to choice of parameters of the GA/KNN method.** *Bioinformatics* 2001, **17(12):**1131-1142.
26. Liu B, Cui Q, Jiang T, Ma S: **A combinational feature selection and ensemble neural network method for classification of gene expression data.** *BMC Bioinformatics* 2004, **5:**136.
27. Zhang JG, Deng HW: **Gene selection for classification of microarray data based on the Bayes error.** *BMC Bioinformatics* 2007, **8(1):**370.
28. Wang Y, Tetko IV, Hall MA, Frank E, Facius A, Mayer KF, Mewes HW: **Gene selection from microarray data for cancer classifica-**

tion–a machine learning approach. *Comput Biol Chem* 2005, **29(1):**37-46.

29. Tang EK, Suganthan PN, Yao X: **Gene selection algorithms for microarray data based on least squares support vector machine.** *BMC Bioinformatics* 2006, **7:**95.

30. Wang L, Zhu J, Zou H: **Hybrid huberized support vector machines for microarray classification and gene selection.** *Bioinformatics* 2008, **24(3):**412-419.

31. Breiman L: **Bagging predictors.** *Machine Learning* 1996, **24(2):**123-140.

32. InfoMetrix: **Multivariate Data Analysis Version 4.0.** *Pirouette User Guide* 2007.

33. Michiels S, Koscielny S, Hill C: **Prediction of cancer outcome with microarrays: a multiple random validation strategy.** *Lancet* 2005, **365(9458):**488-492.

34. Simon R, Radmacher MD, Dobbin K, McShane LM: **Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification.** *Journal of the National Cancer Institute* 2003, **95(1):**14-18.

35. Wessels LF, Reinders MJ, Hart AA, Veenman CJ, Dai H, He YD, van't Veer LJ: **A protocol for building and evaluating predictors of disease state based on microarray data.** *Bioinformatics* 2005, **21(19):**3755-3762.

36. Ben-Dor A, Bruhn L, Friedman N, Nachman I, Schummer M, Yakhini Z: **Tissue classification with gene expression profiles.** *J Comput Biol* 2000, **7(3–4):**559-583.

37. Vapnik VN: **The Nature of Statistical Learning Theory.** 1st edition. *New York: Springer-Verlag New York, Inc*; 1995.

38. Lutz U, Lutz RW, Lutz WK: **Metabolic profiling of glucuronides in human urine by LC-MS/MS and partial least-squares discriminant analysis for classification and prediction of gender.** *Anal Chem* 2006, **78(13):**4564-4571.

39. Jarvis SE, Barr W, Feng ZP, Hamid J, Zamponi GW: **Molecular determinants of syntaxin 1 modulation of N-type calcium channels.** *Journal of Biological Chemistry* 2002, **277(46):**44399-44407.

40. Gana Dresen IM, Boes T, Huesing J, Neuhaeuser M, Joeckel KH: **New resampling method for evaluating stability of clusters.** *BMC Bioinformatics* 2008, **9:**42.

41. Brehelin L, Gascuel O, Martin O: **Using repeated measurements to validate hierarchical gene clusters.** *Bioinformatics* 2008, **24(5):**682-688.

42. Dudoit S, Fridlyand J: **Bagging to improve the accuracy of a clustering procedure.** *Bioinformatics* 2003, **19(9):**1090-1099.

43. Dettling M: **BagBoosting for tumor classification with gene expression data.** *Bioinformatics* 2004, **20(18):**3583-3593.

44. Peng Y: **A novel ensemble machine learning for robust microarray data classification.** *Comput Biol Med* 2006, **36(6):**553-573.

45. Fu WJ, Carroll RJ, Wang S: **Estimating misclassification error with small samples via bootstrap cross-validation.** *Bioinformatics* 2005, **21(9):**1979-1986.

46. Jiang W, Simon R: **A comparison of bootstrap methods and an adjusted bootstrap approach for estimating the prediction error in microarray classification.** *Stat Med* 2007, **26(29):**5320-5334.

47. Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D, Levine AJ: **Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays.** *Proc Natl Acad Sci USA* 1999, **96(12):**6745-6750.

48. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, *et al.*: **Gene-expression profiles predict survival of patients with lung adenocarcinoma.** *Nat Med* 2002, **8(8):**816-824.

49. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, *et al.*: **Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.** *Proc Natl Acad Sci USA* 2001, **98(24):**13790-13795.

50. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, *et al.*: **Gene expression patterns in human liver cancers.** *Molecular Biology of the Cell* 2002, **13(6):**1929-1939.

51. Gordon GJ, Jensen RV, Hsiao L-L, Gullans SR, Blumenstock JE, Ramaswamy S, Richards WG, Sugarbaker DJ, Bueno R: **Translation of Microarray Data into Clinically Relevant Cancer Diagnostic Tests Using Gege Expression Ratios in Lung Cancer And Mesothelioma.** *Cancer Research* 2002, **62:**4963-4967.

52. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, *et al.*: **Prediction of central nervous system embryonal tumour outcome based on gene expression.** *Nature* 2002, **415(6870):**436-442.

53. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, *et al.*: **The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.** *N Engl J Med* 2002, **346(25):**1937-1947.

54. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, *et al.*: **Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.** *Nat Med* 2002, **8(1):**68-74.

55. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, *et al.*: **Gene expression correlates of clinical prostate cancer behavior.** *Cancer Cell* 2002, **1(2):**203-209.

56. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, *et al.*: **Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.** *Cancer Cell* 2002, **1(2):**133-143.

57. van 't Veer LJ, Dai H, Vijver MJ van de, He YD, Hart AA, Mao M, Peterse HL, Kooy K van der, Marton MJ, Witteveen AT, *et al.*: **Gene expression profiling predicts clinical outcome of breast cancer.** *Nature* 2002, **415(6871):**530-536.

58. Wold S: **Pattern Recognition by Means of Disjoint Principle Components Models.** *Pattern Recognition* 1976, **8:**127-139.